Jazz Pharmaceuticals has followed up its $1bn December acquisition of Italian company Gentium with a new agreement to buy rights to Aerial BioPharma's ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Jazz is paying $125m upfront for the product.
Investors liked the deal: Jazz shares closed 6% up at $146.84 on the news (13 January 2014).





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
